Results 91 to 100 of about 2,751,693 (208)

Pembrolizumab Activity in Tyrosine Kinase Inhibitor–Refractory Metastatic GIST: A Case Report

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Introduction Gastrointestinal stromal tumors (GISTs) are commonly driven by activating mutations in KIT or PDGFRA. Although sequential tyrosine kinase inhibitors (TKIs) have improved outcomes in advanced disease, acquired resistance is common.
Neharika Bandaru   +2 more
wiley   +1 more source

İmatinib: etki mekanizması ve direnç geliştirme mekanizmaları

open access: yes, 2012
İmatinib is a specific drug which was developed for the treatment of chronic myelogenous leukemia (KML) and is the pioneer drug in this area. İmatinib mesylate (Glivec) is a derivative of 2-phenylaminopyrimidine.
M. Merve Tuğlu   +2 more
core   +1 more source

Patterns of multimodal MRD response and toxicity with blinatumomab and tyrosine kinase inhibitors in Philadelphia‐positive acute B‐lymphoblastic leukaemia

open access: yes
British Journal of Haematology, EarlyView.
Sebastian M. Stolz   +6 more
wiley   +1 more source

Repurposing Drugs for Malaria through a Human Dose Prediction: A Case Study with Berzosertib

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1315-1325, November 2026.
Repurposing drugs whose clinical safety has been established offers a valuable approach to reduce the cost and time associated with the development of new drugs for malaria. Here, we investigate the potential to repurpose the anticancer kinase inhibitor berzosertib for the treatment of malaria, by assessing whether a predicted efficacious human dose ...
Devasha Redhi   +5 more
wiley   +1 more source

Mutations Associated with Imatinib Mesylate Resistance - Review

open access: yesFolia Medica, 2018
Abstract Chronic myeloid leukemia (CML) arises from the fusion of the BCR and the ABL1 genes. The BCR gene (chromosome 22q11.2) and the ABL1 gene (chromosome 9q34) fuse together due to reciprocal chromosome translocation forming the Philadelphia chromosome (Ph).
Linev Alexandar J.   +5 more
openaire   +3 more sources

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1338-1347, November 2026.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara   +20 more
wiley   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

open access: yesInternational Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel   +26 more
wiley   +1 more source

What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?

open access: yes, 2023
The lysosomal sequestration of hydrophobic weak-base anticancer drugs is one proposed mechanism for the reduced availability of these drugs at target sites, resulting in a marked decrease in cytotoxicity and consequent resistance.
Petr Mlejnek
core   +1 more source

Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance

open access: yesPharmacology Research & Perspectives
In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy.
Naoki Okamoto   +11 more
doaj   +1 more source

Protein Lactylation in Cancer: From Mechanisms to Therapy

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Increased glycolysis and lactate accumulation promote histone and nonhistone protein lactylation, linking tumor metabolic reprogramming to treatment adaptation. Lactylation enhances DNA repair, suppresses antitumor immunity, strengthens antioxidant defenses, and facilitates cell‐cycle checkpoint escape, collectively promoting resistance to chemotherapy,
Wentian Huang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy